Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Deferred Revenue: 2019-2023

Historic Current Deferred Revenue for Fulcrum Therapeutics (FULC) over the last 4 years, with Sep 2023 value amounting to $600,000.

  • Fulcrum Therapeutics' Current Deferred Revenue rose 50.00% to $600,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $600,000, marking a year-over-year increase of 50.00%. This contributed to the annual value of $934,000 for FY2022, which is 80.17% down from last year.
  • According to the latest figures from Q3 2023, Fulcrum Therapeutics' Current Deferred Revenue is $600,000, which was up 16.96% from $513,000 recorded in Q2 2023.
  • Fulcrum Therapeutics' 5-year Current Deferred Revenue high stood at $14.9 million for Q4 2020, and its period low was $400,000 during Q3 2022.
  • For the 3-year period, Fulcrum Therapeutics' Current Deferred Revenue averaged around $2.4 million, with its median value being $1.0 million (2022).
  • As far as peak fluctuations go, Fulcrum Therapeutics' Current Deferred Revenue surged by 273.78% in 2020, and later tumbled by 89.28% in 2022.
  • Quarterly analysis of 5 years shows Fulcrum Therapeutics' Current Deferred Revenue stood at $4.0 million in 2019, then soared by 273.78% to $14.9 million in 2020, then crashed by 68.40% to $4.7 million in 2021, then crashed by 80.17% to $934,000 in 2022, then spiked by 50.00% to $600,000 in 2023.
  • Its Current Deferred Revenue was $600,000 in Q3 2023, compared to $513,000 in Q2 2023 and $737,000 in Q1 2023.